What to do when the standard fails? Wasn't it enough that the patient suffered from superficial bladder cancer and now a post-TUR recurrence? After standard therapies were contraindicated, have been exhausted or were not tolerated in the first place, second-line treatment with IMMUCOTHEL® is indicated to prevent recurrences in superficial bladder cancer. This immunotherapeutic from biosyn is a safe, efficacious and well-established alternative to BCG. Thanks to its high tolerability and low rate of side effects, patients experience much less distress with IMMUCOTHEL®.